Personalis, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Personalis, Inc. Personalis, Inc. (Nasdaq:PSNL) develops, markets and sells advanced cancer genomic tests and services to pharmaceutical, biopharmaceutical, diagnostics companies, universities, non-profits, government entities and patients in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for minimal residual disease detection, therapy response and recurrence monitoring in solid tumor cancers; ImmunoID NeXT, a tissue-based service combining whole exome and whole transcriptome sequencing with advanced analytics for multi-dimensional tumor and microenvironment analysis; NeXT Personal Dx and NeXT Dx for MRD detection and tumor profiling to guide therapy selection and clinical trials; whole exome and genome sequencing services for diagnostic inputs and population research initiatives; as well as proprietary ACE Technology for enhanced sequencing accuracy across difficult genomic regions. Personalis serves the precision oncology sector, focusing on biomarker discovery, personalized cancer immunotherapies, neoantigen prediction and translational research to support drug development and clinical trials. Founded in 2011 and headquartered in Fremont, California, the company recently expanded its collaboration with Tempus AI, Inc. through a $36 million equity investment in 2024 to accelerate commercialization of ultra-sensitive MRD testing for colorectal cancer; received a $50 million investment from Merck in December 2024, resulting in approximately 16.5% ownership, alongside a multi-year extension of its partnership with Moderna for the ImmunoID NeXT Platform in the V940/mRNA-4157 individualized neoantigen therapy program; and plans reimbursement submissions for NeXT Personal products to CMS in late 2024 or early 2025.
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis to Participate in Upcoming Investor Events
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis Q1 Earnings Call Highlights
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis Reports First Quarter Results and Recent Highlights
Personalis to Announce First Quarter 2026 Financial Results
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Personalis to Participate in the 25th Annual Needham Virtual Conference